NASDAQ: GDTCCytomed Therapeutics Ltd Stock
$2.47-0.08 (-3.14%)
Updated Jan 23, 2025
GDTC Price
$2.47
Fair Value Price
-$2.07
Market Cap
$28.50M
52 Week Low
$1.20
52 Week High
$4.19
P/E
-12.17x
P/B
3.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$2.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$2M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GDTC Overview
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GDTC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
B
Sentiment
D
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GDTC
Ranked#75 of 556
Ranked#75 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.14 | A | |
| $122.48 | A | |
| $5.98 | A |
Be the first to know about important GDTC news, forecast changes, insider trades & much more!
GDTC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GDTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDTC ($2.47) is overvalued by 219.19% relative to our estimate of its Fair Value price of -$2.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GDTC ($2.47) is not significantly undervalued (219.19%) relative to our estimate of its Fair Value price of -$2.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GDTC due diligence checks available for Premium users.
Valuation
GDTC fair value
Fair Value of GDTC stock based on Discounted Cash Flow (DCF)
Price
$2.47
Fair Value
-$2.07
Undervalued by
219.19%
GDTC ($2.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GDTC ($2.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.17x
Industry
-205.94x
Market
30.03x
GDTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.59x
Industry
4.95x
GDTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GDTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.0M
Liabilities
$550.6k
Debt to equity
0.07
GDTC's short-term assets ($6.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDTC's short-term assets ($6.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GDTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GDTC vs Biotech Stocks
Cytomed Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.